Evidence map›Paper›PMID 26419770›Full record

ArticleJournal of the American Society for Mass Spectrometry2015

Mapping of Fab-1:VEGF Interface Using Carboxyl Group Footprinting Mass Spectrometry.

Aaron T Wecksler, Matt S Kalo, Galahad Deperalta

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of the American Society for Mass Spectrometry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Aaron T WeckslerProtein Analytical Chemistry Department, Genentech Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.
Matt S KaloProtein Analytical Chemistry Department, Genentech Inc., 1 DNA Way, South San Francisco, CA, 94080, USA.
Galahad DeperaltaProtein Analytical Chemistry Department, Genentech Inc., 1 DNA Way, South San Francisco, CA, 94080, USA. deperalta.galahad@gene.com.ORCID http://orcid.org/0000-0001-9119-6763

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A proof-of-concept study was performed to demonstrate that carboxyl group footprinting, a relatively simple, bench-top method, has utility for first-pass analysis to determine epitope regions of therapeutic mAb:antigen complexes. The binding interface of vascular endothelial growth factor (VEGF) and the Fab portion of a neutralizing antibody (Fab-1) was analyzed using carboxyl group footprinting with glycine ethyl ester (GEE) labeling. Tryptic peptides involved in the binding interface between VEGF and Fab-1 were identified by determining the specific GEE-labeled residues that exhibited a reduction in the rate of labeling after complex formation. A significant reduction in the rate of GEE labeling was observed for E93 in the VEGF tryptic peptide V5, and D28 and E57 in the Fab-1 tryptic peptides HC2 and HC4, respectively. Results from the carboxyl group footprinting were compared with the binding interface identified from a previously characterized crystal structure (PDB: 1BJ1). All of these residues are located at the Fab-1:VEGF interface according to the crystal structure, demonstrating the potential utility of carboxyl group footprinting with GEE labeling for mapping epitopes. Graphical Abstract ᅟ.

Indexed as

AnimalsAntibodies, NeutralizingBinding Sites, AntibodyEpitope MappingEpitopesHumansMass SpectrometryMiceModels, MolecularVascular Endothelial Growth Factor AAntibodies, NeutralizingEpitopesVascular Endothelial Growth Factor ACarboxyl group footprinting mass spectrometryEpitope mappingGlycine ethyl ester labelingVascular endothelial growth factor

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.